Johnson & Johnson Launches Shockwave C2 Aero IVL System Amid Intensifying Global Competition

Disclosed by Stryker8.35Billion-dollar AcquisitionAVSOn the same day, Johnson & Johnson globally launchedIVLHeavyweight New Products, Two Giants inIVLThe showdown on the track is about to unfold.

01

Johnson & Johnson Official AnnouncementShockwave C2 Aero

IVLA New Powerful Tool in the Field

5Month12Date, Johnson & Johnson announced:Will be launched globallyShockwave C2 AeroCoronary Intravascular Lithotripsy Catheter。

IVLSeen as a breakthrough technology in the treatment of calcified lesions, the enormous market potential has, in recent years, led to a rush among major medical device giants to make their moves.Johnson & Johnson in2024Year131Billion-dollar AcquisitionIVLPioneerShockwave Medical, occupying the first-mover advantage.

As one of the earliest to achieveIVLTechnology commercialization enterprises,ShockwaveStill Dominating the Market After Being Acquired. In the first quarter of this year,shockwaveIncome3.05Billion USD, Year-on-Year Growth18.5%, becoming the fastest-growing business segment of Johnson & Johnson Medical Technology.

Shockwave C2 AeroPositioned as“The5On behalf of the platform”. The latest announcement mentioned that in145In the clinical trial of example patients,C2 AeroAchieved98.6%The surgical success rate has been improved while maintaining a safety profile comparable to the previous generation of products.

At this stage,IVLThe track is heating up rapidly, and Johnson & Johnson's advantages are being challenged.

Johnson & JohnsonShockwave MedicalPresidentIsaac ZachariasIndicates:“As other companies prepare to enter the coronary arteryIVLMarketJohnson & Johnson is raising the bar with our fifth-generation platform, built on years of physician feedback, continuous advancements in research and development, and robust clinical validation of our unique mechanism of action.Consolidate our position inIVLLeadership in the field.”

From the latest announcement,C2 AeroThe core upgrade focuses on addressing clinical pain points such as performance, repositioning, and efficiency output, thereby building a market moat. It is reported that the product has already been launched in the United States and Japan, and will be available in Europe and Canada in the coming months.

02

Giants Compete on the Same Stage

IVLFires of War Erupting Everywhere

In the presentIVLMarket,“A Monopoly”The pattern is no longer sustainable.

As the latest challenger,Stryker8.35Billion-dollar acquisitionAVSPowerful EntryIVL. But it is worth noting that Stryker did not directly compete with Johnson & Johnson in the coronary field.“Die-hard”, but instead focused on peripheral blood vessels.

From the resource flow in recent years, peripheral vascular intervention has been a key expansion direction for Stryker. In the first quarter of this year, Stryker's vascular intervention business revenue...5.17USD billion, year-on-year growth27.3%, becoming the fastest-growing sector.

In addition, withShockwaveDifferent technical routes, Stryker bets onAVS Pulse IVLAdopting a purely mechanical action mechanism, it has potential advantages in treatment speed, revealing its ambition to overtake competitors.Pulse IVLThe system is still in the clinical trial stage, and its acceptance in both clinical and market aspects remains to be verified.

Compared with Stryker, Boston Scientific and Abbott pose more direct pressure on Johnson & Johnson.

Boston Scientific has alsoShockwaveWith great interest, but failed to achieve the wish due to various factors,Immediately adjust the direction to2025Year Take DownBolt Medical，Advancing on Both Coronary and Peripheral Fronts, currently its development ofIVLProductSeismiqThe first batch of commercial cases in the coronary field has been completed.FRACTUREThe pivotal trial has also completed enrollment.

Abbott AdvancesIVLThe track also starts with acquisitions,In2023Year8.9Billion-dollar AcquisitionCardiovascular Systems, is one of the earliest giants to bet on this track. Different from Stryker and Boston Scientific's focus,Abbott Focuses More on the Coronary Intervention Field, Coronary Artery under its umbrellaIVLSystem has been acquiredFDA IDEApproval.

Imaging giant Philips inIVLThe layout is even more unique, integrating laser plaque removal and shockwave lithotripsy into the same catheter, which has also entered the clinical research stage.

IVLThe track has officially entered an era of fierce competition.